Nogapendekin alfa inbakicept (ANKTIVA®; nogapendekin alfa inbakicept-pmln) 是一种重组白介素 15 (IL-15) 超级激动剂蛋白复合物，由 ImmunityBio, Inc. 的间接全资子公司 Altor BioScience, LLC 开发，用于治疗实体癌和血液癌以及艾滋病毒感染。 2024年4月，nogapendekin alfa inbakicept被批准与卡介苗（BCG）一起使用，用于治疗伴有或不伴有乳头状肿瘤的原位癌（CIS）的卡介苗无反应的非肌层浸润性膀胱癌（NMIBC）成年患者在美国。本文总结了 nogapendekin alfa inbakicept 开发过程中的里程碑，该里程碑导致首次批准用于癌症治疗。© 2024。作者，获得 Springer Nature Switzerland AG 的独家许可。

Nogapendekin alfa inbakicept (ANKTIVA®; nogapendekin alfa inbakicept-pmln) is a recombinant interleukin-15 (IL-15) superagonist protein complex being developed by Altor BioScience, LLC, an indirect wholly owned subsidiary of ImmunityBio, Inc., for the treatment of solid and haematological cancers and HIV infection. In April 2024, nogapendekin alfa inbakicept was approved for use with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours in the USA. This article summarizes the milestones in the development of nogapendekin alfa inbakicept leading to this first approval for the treatment of cancer.© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.